CytomX Therapeutics, Inc. (FRA:6C1)
Germany flag Germany · Delayed Price · Currency is EUR
4.876
+0.470 (10.67%)
Last updated: Jan 28, 2026, 8:02 AM CET

CytomX Therapeutics Ratios and Metrics

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jan '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
811789499248248
Market Cap Growth
1143.46%-17.12%-5.05%-60.17%0.37%-26.43%
Enterprise Value
695-25-68-65606
Last Close Price
4.731.021.371.463.915.66
PE Ratio
33.982.53----
PS Ratio
8.380.581.031.997.574.43
PB Ratio
8.87-176.77-2.19-1.23-615.53-38.95
P/TBV Ratio
8.98-----
P/FCF Ratio
-----102.63
P/OCF Ratio
-----57.57
EV/Sales Ratio
7.27---1.840.11
EV/FCF Ratio
-11.28----2.48
Debt / Equity Ratio
0.05-20.58-0.29-0.21-47.22-3.20
Debt / EBITDA Ratio
0.200.31----
Debt / FCF Ratio
-----8.43
Asset Turnover
0.770.860.440.180.110.20
Quick Ratio
3.541.211.141.513.934.65
Current Ratio
3.641.251.171.553.994.76
Return on Equity (ROE)
66.76%-----299.13%
Return on Assets (ROA)
9.78%9.69%-1.75%-19.54%-20.78%-14.38%
Return on Capital Employed (ROCE)
19.80%71.90%-14.10%-86.70%-44.40%-27.70%
Earnings Yield
2.94%39.54%-0.55%-93.93%-41.01%-21.41%
FCF Yield
-7.60%-107.36%-54.78%-106.42%-42.70%0.97%
Buyback Yield / Dilution
-41.04%-14.82%-12.27%-2.48%-39.01%-1.79%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.